Kymera Therapeutics, Inc. Announces Departure of Richard Chesworth from Chief Scientific Officer, Effective October 22, 2021
September 16, 2021 at 09:02 pm
Share
On September 16th, 2021, Kymera Therapeutics, Inc. announced that Richard Chesworth, its Chief Scientific Officer, will be departing the Company effective as of October 22, 2021.
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâs own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platformâs capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.